October 3, 2022
Chicago 12, Melborne City, USA

The scientist who co-created CRISPR isn’t ruling out engineered babies someday


JD: It doesn’t really matter to me, [but] I am satisfied that we have 45 issued patents, our 40 pending patents, all in the United States. And our 30 European patents are not affected by the regime. And really, look, I’m continuing my research.

AR: I always thought the source of the patent fight was not about money. My own reading of why it was fought so fiercely was that it was not on commercial control but on debtThose who have done scienceAnd true

JD: That’s your guess. It’s hard to say, isn’t it? I don’t know what could be the inspiration for others, obviously, it would be appealing. Obviously, we do not agree with the decision. And obviously, the 30 countries and the Nobel Prize committee don’t agree, if you’re talking about who invented what, first.

AR: What does it tell you about how the patent system works that a person can receive the Nobel Prize but then the patent goes elsewhere? That should mean people?

JD: It doesn’t really make sense to me. I don’t know if it makes sense to other people. I don’t think there are too many questions in the scientific community about what happened.

AR: You are the subject of a book by Walter Isaacson, who also wrote biographies of Steve Jobs and Leonardo da Vinci. What was it like to be a part of your life?

JD: Humble and a bit scary, if I’m being honest. Although I have to say that I feel lucky that someone as talented as Walter is interested in the story, because he is a great writer. He did a great job trying to capture the feelings of all of us as part of this incredible transformation that happened with CRISPR.

AR: You recently became the chief science consultant for a Wall Street firm called Sixth Street. What are you planning to do there and why did you take on that role?

JD: I’m excited that at Sixth Street we can identify the right team, the right opportunity, the right opening where financing can really accelerate science and business opportunities. One area where I think there is a lot of potential is to analyze the data that is coming out of CRISPR using machine learning. We know that one of the most important opportunities in the future with CRISPR is the understanding of genomics, the function of genes. And obviously not individual genes but complete sets of genes and pathways and broadly different cell types. The types of data that come from these efforts clearly contain a lot of information, most of which is fine. And so mining these types of data sets using machine-learning algorithms, I think, would be very powerful. You can imagine the genetics of the disease আমাদের our personal susceptibility এবং and the use of such techniques to identify new therapeutics.

AR: I always think of you as a scientist. I once saw a picture of you leaning on a student’s shoulder, and I think you are that person. But it tells you to do something a little different. In contrast to the most intriguing scientific question, why do you think you can be good at picking technology for commercial investment?

JD: I love science, and my best days are when I lean on a student in the lab towards data. But I have come to realize that the right parties need real capital to make the impact of CRISPR over the next decade.

AR: A survey by Harvard Business Review found that only 2.3% of VC money goes to women-led startups. Were you shocked to find out?


Source link

Leave feedback about this

  • Quality
  • Price
  • Service


Add Field


Add Field
Choose Image
Choose Video